AIM
VIRX

Advantage Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Advantage Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10
Closed -$1K – 975
2016
Q2 		$1K Hold
10
– – ﹤0.01% 848
2016
Q1 		$1K Hold
10
– – ﹤0.01% 843
2015
Q4 		$2K Hold
10
– – ﹤0.01% 792
2015
Q3 		$2K Hold
10
– – ﹤0.01% 765
2015
Q2 		$6K Hold
10
– – ﹤0.01% 677
2015
Q1 		$5K Buy
+10
New +$5.04K ﹤0.01% 699

Other funds holding VIRX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Advantage Investment Management's VIRX Position: Q3 2016 in Review

Advantage Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2016, closing a stake of 10 shares — an estimated $1K sold.

Advantage Investment Management first reported a position in VIRX in Q1 2015 and held it in 6 quarters. The position peaked at $6K in Q2 2015. 40 funds tracked by Wall St. Rank hold VIRX as of Q3 2016.

  • Advantage Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Advantage Investment Management sold 10 Viracta Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $1K.
  • Advantage Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2015 and held it in 6 quarters.
  • Advantage Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $6K in Q2 2015.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Advantage Investment Management's 13F filing for Q3 2016, filed 27 Mar 2017.